Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial
Jia Liu, Wei Yang, Yue Liu, Cheng Lü, Lianguo Ruan, Chen Zhao, Ruili Huo, Xin Shen, Qing Miao, Wenliang Lv, Hao Li, Huaxin Shi, Lijie Hu, Zhixu Yang, Li Zhang, Bing Wang, Guoju Dong, Yongyue Xian, Bin Li, Ryan Zhenqi Zhou, Chunyan Xu, Yingying Chen, Yongjun Bian, Jing Guo, Jinliang Yang, Jian Wang, Wensheng Qi, Suping Chen, Yang Chen, Bei Yan, Wei Wang, Jing Li, Xiaolei Xie, Ming Xu, Jianxin Jiang, Gang Wang, Xiaodong Cong, Haoning Zhu, Jiaheng Shi, Luxing Leng, Dongxu Li, Lanping Guo, Luqi Huang
Topics & Concepts
Interquartile rangeMedicineRandomized controlled trialInternal medicineCoronavirus disease 2019 (COVID-19)Adverse effectSingle CenterViral loadClinical trialGastroenterologyDiseaseVirusImmunologyInfectious disease (medical specialty)Long-Term Effects of COVID-19COVID-19 Clinical Research StudiesPharmacological Receptor Mechanisms and Effects